NCoR controls glioblastoma tumor cell characteristics

Neuro-Oncology

Volumn 16, Issue 2, 2014, Pages 241-249

  Heldring, Nina ^a   Nyman, Ulrika ^a   Lönnerberg, Peter ^a   Önnestam, Sofie ^a   Herland, Anna ^a   Holmberg, Johan ^a   Hermanson, Ola ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

autophagy; ChIP seq; EMT; invasion; tumor formation

Indexed keywords

BECLIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NCOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; AUTOPHAGY; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR GROWTH;

AUTOPHAGY; CHIP-SEQ; EMT; INVASION; TUMOR FORMATION;

ANIMALS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NUCLEAR RECEPTOR CO-REPRESSOR 1; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893078984     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not214     Document Type: Article

References (27)

1. Hermanson O, Jepsen K, Rosenfeld MG. N-CoR controls differentiation of neuralstemcells into astrocytes.Nature. 2002;419(6910):934-939.
2. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645-648.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983-3988.
5. Nduom EK, Hadjipanayis CG, Van Meir EG. Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment. Cancer J. 2012;18(1):100-106.
6. Hertwig F, Meyer K, Braun S, et al. Definition of genetic events directing the development of distinct types of brain tumors from postnatal neural stem/progenitor cells. Cancer Res. 2012;72(13):3381-3392.
7. Lu J, Zhuang Z, Song DK, et al. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J Neurosurg. 2010; 113(2):225-233.
8. Park DM, Li J, Okamoto H, et al. N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle. 2007;6(4):467-470.
9. Ai T, Cui H, Chen L. Multi-targeted histone deacetylase inhibitors in cancer therapy. Curr Med Chem. 2012;19(4):475-487.
10. Shabason JE, Tofilon PJ, Camphausen K. Grand rounds at the National Institutes of Health:HDAC inhibitors as radiation modifiers, frombench to clinic. J Cell Mol Med. 2011;15(12):2735-2744.
11. Taddei ML, Giannoni E, Fiaschi T, Chiarugi P. Anoikis: an emerging hallmark in health and diseases. J Pathol. 2012;226(2):380-393.
12. Newton HB, Rosenblum MK, Walker RW. Extraneural metastases of infratentorial glioblastoma multiforme to the peritoneal cavity. Cancer-Am Cancer Soc. 1992;69(8):2149-2153.
13. Holmberg J, He X, Peredo I, et al. Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PLoS One. 2011;6(3):e18454.
14. Nister M, Libermann TA, Betsholtz C, et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res. 1988;48(14):3910-3918.
15. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
16. Ji H, Jiang H, Ma W, Johnson DS, Myers RM, Wong WH. An integrated software system for analyzing ChIP-chip and ChIP-seq data. Nat Biotechnol. 2008;26(11):1293-1300.
17. Castro DS, Hermanson E, Joseph B, et al. Induction of cell cycle arrest and morphological differentiation by Nurr1 and retinoids in dopamine MN9D cells. J Biol Chem. 2001;276(46):43277-43284.
18. Rutka JT, Ivanchuk S, Mondal S, et al. Co-expression of nestin and vimentin intermediate filaments in invasive human astrocytoma cells. Int J Dev Neurosci. 1999;17(5-6):503-515.
19. Li J, Zhuang Z, Okamoto H, et al. Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers. Neurology. 2006;66(5):733-736.
20. Perissi V, Jepsen K, Glass CK, Rosenfeld MG. Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet. 2010;11(2): 109-123.
21. Satelli A, Li S. Vimentin in cancerand its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033-3046.
22. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21(Suppl 7):vii89-vii92.
23. Jacquel A, Obba S, Boyer L, et al. Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. Blood. 2012;119(19):4527-4531.
24. Vessoni AT, Muotri AR, Okamoto OK. Autophagy in stem cell maintenance and differentiation. Stem Cells Dev. 2012;21(4): 513-520.
25. Yoo JY, Choi HK, Choi KC, et al. Nuclear hormone receptor corepressor promotes esophageal cancer cell invasion by transcriptional repression of interferon-gamma-inducible protein 10 in a casein kinase 2-dependent manner. Mol Biol Cell. 2012;23(15): 2943-2954.
26. Ogawa S, Lozach J, Jepsen K, et al. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc Natl Acad Sci USA. 2004;101(40):14461-14466.
27. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1): 98-110.